ATHEROGENICS INC, (AGIX) Stock Research Free Stock Rating

Company Profile

AtheroGenics, Inc. engages in the discovery, development, and commercialization of therapeutics for the treatment of chronic inflammatory diseases, including coronary heart disease, organ transplant rejection, rheumatoid arthritis, and asthma. It owns a proprietary vascular protectant technology (v-protectant) platform to discover drugs to treat these types of diseases. Based on this v-protectant platform, the company has two drug development programs. The company’s AGI-1067 is a v-protectant candidate that is designed to benefit patients with coronary heart disease, which is atherosclerosis of the blood vessels of the heart. Its AGI-1067 is also being evaluated in the pivotal Phase III clinical trials called ARISE, as an oral therapy for the treatment of atherosclerosis. AtheroGenics’ AGI-1096, a v-protectant candidate, is an antioxidant and selective anti-inflammatory agent for accelerated inflammation of grafted blood vessels. AGI-1096 inhibits the expression of certain inflammatory proteins, including VCAM-1, in endothelial cells lining the inside surfaces of blood vessel walls. In addition, AtheroGenics has preclinical programs in rheumatoid arthritis and asthma using its v-protectant platform. The company has collaboration agreement with Astellas Pharma. AtheroGenics was organized in 1993 and is headquartered in Alpharetta, Georgia.

Latest Headlines